Identification of a clinically relevant androgen-dependent gene signature in prostate cancer

Hannelore V. Heemers, Lucy J. Schmidt, Zhifu Sun, Kevin M. Regan, S. Keith Anderson, Kelly Duncan, Dan Wang, Song Liu, Karla V. Ballman, Donald J. Tindall

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

The androgen receptor (AR) is the principal target for treatment of non-organ-confined prostate cancer (PCa). Androgen deprivation therapies (ADT) directed against the AR ligand-binding domain do not fully inhibit androgen-dependent signaling critical for PCa progression. Thus, information that could direct the development of more effective ADTs is desired. Systems and bioinformatics approaches suggest that considerable variation exists in the mechanisms by which AR regulates expression of effector genes, pointing to a role for secondary transcription factors. A combination of microarray and in silico analyses led us to identify a 158-gene signature that relies on AR along with the transcription factor SRF (serum response factor), representing less than 6% of androgen-dependent genes. This AR-SRF signature is sufficient to distinguish microdissected benign and malignant prostate samples, and it correlates with the presence of aggressive disease and poor outcome. The ARSRF signature described here associates more strongly with biochemical failure than other AR target gene signatures of similar size. Furthermore, it is enriched in malignant versus benign prostate tissues, compared with other signatures. To our knowledge, this profile represents the first demonstration of a distinct mechanism of androgen action with clinical relevance in PCa, offering a possible rationale to develop novel and more effective forms of ADT.

Original languageEnglish (US)
Pages (from-to)1978-1988
Number of pages11
JournalCancer research
Volume71
Issue number5
DOIs
StatePublished - Mar 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Identification of a clinically relevant androgen-dependent gene signature in prostate cancer'. Together they form a unique fingerprint.

Cite this